These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1717801)

  • 1. Alfuzosin for benign prostatic hypertrophy.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Oct; 338(8772):947. PubMed ID: 1717801
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alfuzosin in the treatment of benign prostatic hypertrophy].
    Jardin A
    J Urol (Paris); 1993; 99(6):308-10. PubMed ID: 7516375
    [No Abstract]   [Full Text] [Related]  

  • 3. Alfuzosin for benign prostatic hypertrophy.
    Chapple CR
    Lancet; 1991 Jul; 338(8760):182. PubMed ID: 1712882
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
    Hansen BJ; Meyhoff HH
    Ugeskr Laeger; 1992 Feb; 154(6):361-2. PubMed ID: 1371629
    [No Abstract]   [Full Text] [Related]  

  • 5. Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2004 Jan; 46(1173):1-2. PubMed ID: 14691408
    [No Abstract]   [Full Text] [Related]  

  • 6. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 8. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Wyllie MG
    BJU Int; 2003 Dec; 92(9):1044; author reply 1044-5. PubMed ID: 14632873
    [No Abstract]   [Full Text] [Related]  

  • 11. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.
    Hansen BJ
    J Urol; 1996 Jul; 156(1):184-5. PubMed ID: 8648797
    [No Abstract]   [Full Text] [Related]  

  • 14. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin for the management of benign prostate hyperplasia.
    Weiner DM; Lowe FC
    Expert Opin Pharmacother; 2003 Nov; 4(11):2057-63. PubMed ID: 14596659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.